AbbVie Inc. — Revenue by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5a115a88-9847-495c-89bf-fb5da284752e/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $61.2B | 2025-01-01 – 2025-12-31 | evidence 0001551152-26-000008 |
| FY 2024 | $56.3B | 2024-01-01 – 2024-12-31 | evidence 0001551152-25-000020 |
| FY 2023 | $54.3B | 2023-01-01 – 2023-12-31 | evidence 0001551152-24-000011 |
| FY 2022 | $58.1B | 2022-01-01 – 2022-12-31 | evidence 0001551152-23-000011 |
| FY 2021 | $56.2B | 2021-01-01 – 2021-12-31 | evidence 0001551152-22-000007 |
| FY 2020 | $45.8B | 2020-01-01 – 2020-12-31 | evidence 0001551152-21-000008 |
| FY 2019 | $33.3B | 2019-01-01 – 2019-12-31 | evidence 0001551152-20-000007 |
| FY 2018 | $32.8B | 2018-01-01 – 2018-12-31 | evidence 0001551152-19-000008 |
| FY 2017 | $28.2B | 2017-01-01 – 2017-12-31 | evidence 0001551152-19-000008 |
| FY 2016 | $25.6B | 2016-01-01 – 2016-12-31 | evidence 0001551152-19-000008 |
| FY 2015 | $22.9B | 2015-01-01 – 2015-12-31 | evidence 0001047469-16-010239 |
| FY 2014 | $20.0B | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-000995 |
| FY 2013 | $18.8B | 2013-01-01 – 2013-12-31 | evidence 0001047469-14-001154 |
| FY 2012 | $18.4B | 2012-01-01 – 2012-12-31 | evidence 0001047469-14-001154 |
| FY 2011 | $17.4B | 2011-01-01 – 2011-12-31 | evidence 0001047469-14-001154 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).